Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Agios Pharmaceuticals stock price, quote, forecast and news

AGIO
US00847X1046
A1W2RM

Price

49.03
Today +/-
+2.19
Today %
+5.10 %
P

Agios Pharmaceuticals stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Agios Pharmaceuticals stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Agios Pharmaceuticals stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Agios Pharmaceuticals stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Agios Pharmaceuticals's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Agios Pharmaceuticals Stock Price History

DateAgios Pharmaceuticals Price
9/25/202449.03 undefined
9/24/202446.59 undefined
9/23/202445.76 undefined
9/20/202446.55 undefined
9/19/202447.38 undefined
9/18/202445.54 undefined
9/17/202445.69 undefined
9/16/202445.41 undefined
9/13/202446.69 undefined
9/12/202444.92 undefined
9/11/202444.31 undefined
9/10/202444.52 undefined
9/9/202443.93 undefined
9/6/202443.28 undefined
9/5/202444.04 undefined
9/4/202444.75 undefined
9/3/202444.73 undefined
8/30/202445.91 undefined
8/29/202445.86 undefined
8/28/202445.36 undefined

Agios Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Agios Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Agios Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Agios Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Agios Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Agios Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Agios Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Agios Pharmaceuticals’s growth potential.

Agios Pharmaceuticals Revenue, EBIT and net profit per share

DateAgios Pharmaceuticals RevenueAgios Pharmaceuticals EBITAgios Pharmaceuticals Net Income
2029e1.01 B undefined0 undefined87.62 M undefined
2028e699.25 M undefined70.21 M undefined70.99 M undefined
2027e443.18 M undefined-110.18 M undefined-106.63 M undefined
2026e186.79 M undefined-339.91 M undefined-297.85 M undefined
2025e106.79 M undefined-394.64 M undefined-353.97 M undefined
2024e38.84 M undefined-268.32 M undefined-286.66 M undefined
202326.82 M undefined-391.49 M undefined-352.09 M undefined
202214.24 M undefined-389.04 M undefined-231.8 M undefined
20210 undefined-378.42 M undefined1.6 B undefined
20200 undefined-335.92 M undefined-327.37 M undefined
20190 undefined-316.27 M undefined-411.47 M undefined
201894.39 M undefined-362.48 M undefined-346.03 M undefined
201743.01 M undefined-320.79 M undefined-314.67 M undefined
201669.89 M undefined-200.99 M undefined-198.47 M undefined
201559.12 M undefined-118.7 M undefined-117.73 M undefined
201465.36 M undefined-54.13 M undefined-53.5 M undefined
201325.55 M undefined-38.88 M undefined-43.57 M undefined
201225.11 M undefined-23 M undefined-27.29 M undefined
201121.84 M undefined-16.63 M undefined-26.81 M undefined

Agios Pharmaceuticals Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (B)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
0.020.030.030.070.060.070.040.090000.010.030.040.110.190.440.71.01
-19.05-160.00-9.2316.95-37.68118.60----85.7146.15178.9575.47138.1757.7944.92
-------97.87---85.7188.46------
0000000920001223000000
-16-23-38-54-118-200-320-362-316-335-378-389-391-268-394-339-110700
-76.19-92.00-152.00-83.08-200.00-289.86-744.19-385.11----2,778.57-1,503.85-705.26-371.70-182.26-24.8310.01-
-0.03-0.03-0.04-0.05-0.12-0.2-0.31-0.35-0.41-0.331.6-0.23-0.35-0.29-0.35-0.3-0.110.070.09
-3.8559.2623.26120.7569.2358.5910.1918.79-20.44-590.52-114.4052.38-18.7523.43-15.86-64.31-166.0424.29
3.013.415.4233.6737.4339.1346.5957.4259.996960.4554.7955.65000000
-------------------
Details

Keystats

ⓘ

Revenue and Growth

The Agios Pharmaceuticals Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Agios Pharmaceuticals is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (B)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (k)SHORT-TERM REC. (M)LONG-T. LIAB. (k)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (B)
2011201220132014201520162017201820192020202120222023
                         
0.180.130.170.340.320.540.420.590.560.571.020.780.78
0000001.27.311.921.302.22.81
0000002.63.13.44.1000
00000000.97.314.708.519.08
11.42.12.58.68.710.317.517.224.223.739.83935.02
0.190.130.170.350.330.550.450.610.610.641.060.830.83
3.23.63.86.423.225.324.424.3126.1117.5104.288.169.79
0027.1125.458.932.3143.8220.1152.997.6266.4313.929.44
0000000000000
0000000000000
0000000000000
0.73.30.60.60.61.60.90.201.12.944.06
3.96.931.5132.482.759.2169.1244.6279216.2373.5406103.28
0.190.140.20.480.410.610.610.860.890.851.431.240.94
                         
115.9115.9000000.10.10.10.10.10.07
000.240.590.630.841.171.792.162.242.332.392.44
-53.9-74-113.4-166.9-284.7-483.2-798.1-1,104.6-1,516.1-1,843.5-238.8-470.6-822.65
000-100-300-300-1,400-2,200200100-1,200-12,500-441
0000000000000
0.060.040.130.420.350.360.380.690.640.42.091.91.61
3.63.33.711.114.717.122.817.921.926.816.718.69.78
1.51.76.61416323442.159.867.242.84458.18
4330.126.73622.139.338.133.510.90000
0000000000000
0000000030030030000
48.135.13761.152.888.494.993.592.994.359.862.667.96
0000000070030030000
0000000000000
83.25832.86.422.1172.114477.4156.7358.785.775.358.14
83.25832.86.422.1172.114477.4157.43598675.358.14
131.393.169.867.574.9260.5238.9170.9250.3453.3145.8137.9126.1
0.190.140.20.490.420.620.610.860.890.852.242.041.74
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Agios Pharmaceuticals provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Agios Pharmaceuticals's financial health and stability.

Assets

Agios Pharmaceuticals's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Agios Pharmaceuticals must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Agios Pharmaceuticals after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Agios Pharmaceuticals's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (B)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (B)CASH FLOW FROM OTHER INVESTING ACTIVITIES (B)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2011201220132014201520162017201820192020202120222023
-0.02-0.02-0.04-0.05-0.12-0.2-0.31-0.35-0.41-0.331.6-0.23-0.35
0111356789986
-10630000000000
17-38-25-22-10188-24-35-46-71-36-16-19
11627808495142136159-1,930-20113
0000000000000
0305000000001
-15-49-56-59-7638-285-304-370-290-407-309-296
-1-1-1-2-20-9-4-6-12-14-5-40
-0.020.02-0.09-0.330.13-0.12-0.06-0.270.090.081.250.240.24
-0.020.02-0.09-0.330.15-0.11-0.05-0.270.10.091.250.250.24
0000000000000
0000000000000
770126335617028454628911-76525
7701233356169285546289261-76525
00-2000000250000
0000000000000
39-26-19-575788-58-32104675-63-51
-17.13-51.03-57.69-61.57-97.1128.64-289.86-311.41-382.79-305.67-413.06-314.36-297.06
0000000000000

Agios Pharmaceuticals stock margins

The Agios Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Agios Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Agios Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Agios Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Agios Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Agios Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Agios Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Agios Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Agios Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Agios Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Agios Pharmaceuticals Margin History

Agios Pharmaceuticals Gross marginAgios Pharmaceuticals Profit marginAgios Pharmaceuticals EBIT marginAgios Pharmaceuticals Profit margin
2029e89.26 %0 %8.65 %
2028e89.26 %10.04 %10.15 %
2027e89.26 %-24.86 %-24.06 %
2026e89.26 %-181.98 %-159.46 %
2025e89.26 %-369.55 %-331.46 %
2024e89.26 %-690.84 %-738.05 %
202389.26 %-1,459.52 %-1,312.63 %
202288.06 %-2,732.02 %-1,627.81 %
202189.26 %0 %0 %
202089.26 %0 %0 %
201989.26 %0 %0 %
201898.52 %-384.02 %-366.6 %
201789.26 %-745.85 %-731.62 %
201689.26 %-287.58 %-283.97 %
201589.26 %-200.78 %-199.14 %
201489.26 %-82.82 %-81.85 %
201389.26 %-152.17 %-170.53 %
201289.26 %-91.6 %-108.68 %
201189.26 %-76.14 %-122.76 %

Agios Pharmaceuticals Stock Sales Revenue, EBIT, Earnings per Share

The Agios Pharmaceuticals earnings per share therefore indicates how much revenue Agios Pharmaceuticals has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Agios Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Agios Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Agios Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Agios Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Agios Pharmaceuticals Revenue, EBIT and net profit per share

DateAgios Pharmaceuticals Sales per ShareAgios Pharmaceuticals EBIT per shareAgios Pharmaceuticals Earnings per Share
2029e17.81 undefined0 undefined1.54 undefined
2028e12.29 undefined0 undefined1.25 undefined
2027e7.79 undefined0 undefined-1.87 undefined
2026e3.28 undefined0 undefined-5.24 undefined
2025e1.88 undefined0 undefined-6.22 undefined
2024e0.68 undefined0 undefined-5.04 undefined
20230.48 undefined-7.03 undefined-6.33 undefined
20220.26 undefined-7.1 undefined-4.23 undefined
20210 undefined-6.26 undefined26.55 undefined
20200 undefined-4.87 undefined-4.74 undefined
20190 undefined-5.27 undefined-6.86 undefined
20181.64 undefined-6.31 undefined-6.03 undefined
20170.92 undefined-6.89 undefined-6.75 undefined
20161.79 undefined-5.14 undefined-5.07 undefined
20151.58 undefined-3.17 undefined-3.15 undefined
20141.94 undefined-1.61 undefined-1.59 undefined
20131.66 undefined-2.52 undefined-2.83 undefined
20127.39 undefined-6.76 undefined-8.03 undefined
20117.26 undefined-5.52 undefined-8.91 undefined

Agios Pharmaceuticals business model

Agios Pharmaceuticals Inc. is a US biopharmaceutical company specializing in the development of treatment options for rare genetic disorders and cancer. The company was founded in 2008 by David Schenkein, Lewis Cantley, and Tak Mak and is headquartered in Cambridge, Massachusetts. The history of Agios Pharmaceuticals Inc. began with the discovery of IDH1 mutations, which are frequently found in many types of cancer. The founders of Agios recognized the significance of this discovery and laid the foundation for the development of drugs targeting this mutation. Agios' business model is to develop innovative therapeutics for diseases that are often neglected by other companies. The company focuses on researching enzymes that play important roles in genetic disorders and cancer processes. Agios collaborates closely with other companies and research institutions to quickly translate its research findings into clinical research and subsequent patient treatment. Additionally, the company has established itself as a pioneer in the application of artificial intelligence in drug development in recent years. Agios divides its portfolio into two main areas: oncology and rare genetic disorders. In oncology, the company utilizes targeted therapies based on a deep understanding of the underlying cancer biology. Therapeutic approaches include enzyme inhibitors, immunotherapies, and cell therapies. Agios has several promising candidates in clinical development in this area, including Idhifa for the treatment of acute myeloid leukemia, as well as Ivosidenib and Ag-120, both used to treat brain tumors. In the field of rare genetic disorders, Agios specializes in a group of enzyme defects known as citric acid cycle disorders. Agios is the only provider of drugs targeting these enzymes. The company recently received approval for Tibsovo for the treatment of acute myeloid leukemia in the United States. Agios aims to continuously expand its pipeline of therapeutics to meet the unmet need for treatments for rare diseases and cancer. The company has an extensive research pipeline, with several drugs in preclinical and clinical development. Agios works closely with other companies and research institutions to quickly translate its research findings into clinical development and subsequent patient treatment. Overall, Agios Pharmaceuticals has made impressive strides in recent years and has established itself as a key player in the biopharmaceutical industry. The company specializes in developing innovative therapies for rare genetic disorders and cancer and collaborates closely with other companies and research institutions. With its extensive research pipeline and the application of artificial intelligence, Agios is well-positioned to contribute to the development of new therapeutic options in the future. Agios Pharmaceuticals is one of the most popular companies on Eulerpool.com.

Agios Pharmaceuticals SWOT Analysis

Strengths

Agios Pharmaceuticals Inc has several strengths that contribute to its success in the pharmaceutical industry. These include:

  • Strong Research and Development (R&D): Agios Pharmaceuticals Inc invests heavily in R&D, allowing them to develop innovative and effective drugs to address unmet medical needs.
  • Strategic Partnerships: The company has established strategic partnerships with leading pharmaceutical companies, enabling access to resources, expertise, and distribution networks.
  • Talented Workforce: Agios Pharmaceuticals Inc attracts top talent, including scientists and researchers, who drive the company's innovation and drug development efforts.
  • Strong Financial Position: The company boasts a solid financial position, providing stability and the ability to fund ongoing research and development initiatives.

Weaknesses

Agios Pharmaceuticals Inc also faces certain weaknesses that may pose challenges to its business operations and growth. These weaknesses include:

  • Dependence on Limited Product Portfolio: Agios Pharmaceuticals Inc heavily relies on a limited number of drug candidates, which exposes them to greater risk if any of these fail to meet expectations or face regulatory hurdles.
  • Relatively Small Market Presence: Compared to larger pharmaceutical companies, Agios Pharmaceuticals Inc has a smaller market presence, which may limit its ability to compete on a global scale.
  • Regulatory Uncertainty: As with any pharmaceutical company, Agios Pharmaceuticals Inc operates in a highly regulated industry, subject to strict compliance with drug approval processes and changing regulations.

Opportunities

Agios Pharmaceuticals Inc can capitalize on various opportunities in the market to drive growth and success. These opportunities include:

  • Expanding Research Areas: The company can explore new therapeutic areas and expand its drug development efforts beyond the current portfolio, targeting a wider range of diseases and medical conditions.
  • Global Market Expansion: Agios Pharmaceuticals Inc can enter new markets and expand its geographic reach through strategic partnerships or acquisitions, enabling access to larger patient populations.
  • Investing in Technology: By investing in advanced technology and data analytics, Agios Pharmaceuticals Inc can enhance its research capabilities, clinical trials, and improve decision-making processes.

Threats

Agios Pharmaceuticals Inc faces several threats that may impact its business operations and market performance. These threats include:

  • Intense Competition: The pharmaceutical industry is highly competitive, with the presence of established players and emerging biotechnology companies. Agios Pharmaceuticals Inc faces the risk of competitors developing similar drugs or therapeutic solutions.
  • Patent Expirations: The expiration of patents for key drugs in Agios Pharmaceuticals Inc's portfolio can result in the entry of generic competitors, leading to a decline in market share and revenue.
  • Healthcare Reforms: Changes in healthcare policies and reimbursement structures can impact the pricing and accessibility of Agios Pharmaceuticals Inc's drugs, potentially affecting profitability.

Agios Pharmaceuticals Revenue by Segment

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Agios Pharmaceuticals Revenue by Segment

Segmente20232022202020192018
Product revenue, net--121.09 M USD59.85 M USD-
Collaboration revenue – related party--68.27 M USD39.26 M USD-
Royalty revenue – related party--10.26 M USD10.54 M USD-
Collaboration revenue – other--3.57 M USD8.26 M USD-
Collaboration revenue – related party----60.66 M USD
Product revenue, net26.82 M USD11.74 M USD--13.8 M USD
Collaboration revenue – other----12.67 M USD
Royalty revenue – related party----7.22 M USD
Milestone revenue-2.5 M USD---
On-going research and development services---35.95 M USD-
On-going research and development services--64.35 M USD--
Licenses---5 M USD-
Commercialization Activities---3.3 M USD-
Other Services, Non-Performance Obligations---3.03 M USD-
Other services---235,000 USD-
Committee participation-----
Development activities-----
Commercialization Activities--3.93 M USD--
Other Services, Non-Performance Obligations--3.38 M USD--
Other services--192,000 USD--
Committee participation-----
Development activities-----
Licenses-----

Agios Pharmaceuticals Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Agios Pharmaceuticals historical P/E ratio, EBIT, and P/S ratio.

Agios Pharmaceuticals shares outstanding

The number of shares was Agios Pharmaceuticals in 2023 — This indicates how many shares 55.651 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Agios Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Agios Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Agios Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Agios Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Agios Pharmaceuticals.

Agios Pharmaceuticals latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-1.63 -1.69  (-3.39 %)2024 Q2
3/31/2024-1.68 -1.45  (13.79 %)2024 Q1
12/31/2023-1.68 -1.72  (-2.34 %)2023 Q4
9/30/2023-1.74 -1.64  (5.56 %)2023 Q3
6/30/2023-1.59 -1.51  (5.17 %)2023 Q2
3/31/2023-1.74 -1.47  (15.28 %)2023 Q1
12/31/2022-1.65 0.67  (140.64 %)2022 Q4
9/30/2022-1.8 -1.49  (17.18 %)2022 Q3
6/30/2022-1.78 -1.68  (5.68 %)2022 Q2
3/31/2022-1.85 -1.74  (5.81 %)2022 Q1
1
2
3
4
...
5

Eulerpool ESG Scorecard© for the Agios Pharmaceuticals stock

Eulerpool World ESG Rating (EESG©)

62/ 100

🌱 Environment

55

👫 Social

99

🏛️ Governance

32

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
✅

Social

Percentage of female employees59
Percentage of women in management—
Percentage of Asian employees21
Share of Asian management21
Percentage of Hispanic/Latino employees3
Hispano/Latino Management share2
Percentage of Black employees4
Black Management Share5
Percentage of white employees69
White Management Share68
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting✅
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Agios Pharmaceuticals list of shareholders

%
Name
Stocks
Change
Date
9.84341 % The Vanguard Group, Inc.5,599,91786,4061/31/2024
7.58191 % BlackRock Institutional Trust Company, N.A.4,313,348338,17112/31/2023
7.32572 % Farallon Capital Management, L.L.C.4,167,602206,00012/31/2023
7.05045 % Bellevue Asset Management AG4,011,000-2,50012/31/2023
6.19441 % Armistice Capital LLC3,524,000200,00012/31/2023
4.61537 % State Street Global Advisors (US)2,625,685361,85112/31/2023
4.56454 % Dimensional Fund Advisors, L.P.2,596,764137,87312/31/2023
3.78304 % Rock Springs Capital Management LP2,152,17302/14/2024
3.54265 % Macquarie Investment Management2,015,41423,39212/31/2023
3.19677 % First Trust Advisors L.P.1,818,64343,47612/31/2023
1
2
3
4
5
...
10

Agios Pharmaceuticals Executives and Management Board

Mr. Brian Goff54
Agios Pharmaceuticals Chief Executive Officer, Director (since 2022)
Compensation 11.74 M
Dr. Jacqualyn Fouse61
Agios Pharmaceuticals Chairman of the Board (since 2017)
Compensation 4.95 M
Ms. Cecilia Jones48
Agios Pharmaceuticals Chief Financial Officer
Compensation 2.91 M
Ms. Sarah Gheuens44
Agios Pharmaceuticals Head - Research and Development, Chief Medical Officer
Compensation 1.85 M
Mr. James Burns45
Agios Pharmaceuticals Chief Legal Officer
Compensation 1.74 M
1
2
3

Agios Pharmaceuticals Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Certara Stock
Certara
SupplierCustomer0,950,870,590,840,47-
Bristol-Myers Squibb Stock
Bristol-Myers Squibb
SupplierCustomer0,200,67-0,61-0,78-0,30-0,27
CStone Pharmaceuticals Stock
CStone Pharmaceuticals
SupplierCustomer-0,15-0,580,790,67-
1

Most common questions regarding Agios Pharmaceuticals

What values and corporate philosophy does Agios Pharmaceuticals represent?

Agios Pharmaceuticals Inc represents a set of core values and a corporate philosophy that guide its operations. The company is committed to innovation, scientific excellence, and the improvement of patients' lives. Agios focuses on developing medicines for patients with genetically defined diseases, employing a precision medicine approach. With a passion for understanding the biology underlying diseases, Agios strives to provide transformative therapies. By leveraging its deep expertise in cellular metabolism, the company aims to become a leader in the field of metabolic immuno-oncology. Agios Pharmaceuticals Inc is dedicated to making a positive impact through its scientific advancements and dedication to patients' well-being.

In which countries and regions is Agios Pharmaceuticals primarily present?

Agios Pharmaceuticals Inc is primarily present in the United States. The company, headquartered in Cambridge, Massachusetts, focuses on developing innovative medicines to treat serious diseases. With a strong presence in the biopharmaceutical industry, Agios Pharmaceuticals has made significant advancements in the field of cellular metabolism and cancer research. As a leading player in the market, Agios Pharmaceuticals Inc continues to expand its global reach through collaborations and partnerships, aiming to improve patient outcomes worldwide.

What significant milestones has the company Agios Pharmaceuticals achieved?

Agios Pharmaceuticals Inc, a renowned biopharmaceutical company, has achieved remarkable milestones in its journey. Some of its significant accomplishments include the FDA approval of its groundbreaking drug, Tibsovo, for the treatment of acute myeloid leukemia (AML) patients with specific genetic mutations. Additionally, Agios Pharmaceuticals Inc successfully obtained FDA approval for another innovative product, Idhifa, designed to tackle relapsed or refractory AML. These milestone achievements showcase Agios Pharmaceuticals Inc's commitment to developing transformative therapies for critical diseases, solidifying its position as a key player in the pharmaceutical industry.

What is the history and background of the company Agios Pharmaceuticals?

Agios Pharmaceuticals Inc, founded in 2008, is a renowned biopharmaceutical company based in the United States. The company specializes in the discovery and development of novel medicines to treat various severe diseases concerning cancer and rare genetic metabolic disorders. Agios focuses primarily on cellular metabolism, aiming to identify and address metabolic dysregulation underlying such diseases. With its dedicated team of scientists and researchers, Agios has successfully brought several innovative medicines to market, improving the lives of patients worldwide. Recognized for its cutting-edge research and commitment to improving patient outcomes, Agios Pharmaceuticals Inc continues to thrive in the field of biopharmaceuticals.

Who are the main competitors of Agios Pharmaceuticals in the market?

The main competitors of Agios Pharmaceuticals Inc in the market are companies such as Celgene Corporation, Blueprint Medicines Corporation, and Forma Therapeutics Holdings, Inc. These companies operate in the biotechnology and pharmaceutical industry, targeting similar therapeutic areas and developing potential treatments for various diseases and medical conditions. Agios Pharmaceuticals Inc competes with these companies in terms of research and development capabilities, product pipeline, and market presence.

In which industries is Agios Pharmaceuticals primarily active?

Agios Pharmaceuticals Inc is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of Agios Pharmaceuticals?

Agios Pharmaceuticals Inc is a leading biopharmaceutical company focused on discovering and developing novel medicines to treat cancers and rare genetic metabolic disorders. With a unique business model, Agios combines deep scientific expertise and cutting-edge technologies to identify and advance potential therapeutic candidates. The company specializes in cellular metabolism, leveraging its understanding of altered metabolic pathways to develop targeted therapies. Agios aims to address the unmet medical needs of patients by creating innovative treatments that harness the power of metabolism. Through collaboration and clinical development, Agios Pharmaceuticals is dedicated to delivering transformative therapies and improving patient outcomes.

What is the P/E ratio of Agios Pharmaceuticals 2024?

The Agios Pharmaceuticals P/E ratio is -9.52.

What is the P/S ratio of Agios Pharmaceuticals 2024?

The Agios Pharmaceuticals P/S ratio is 70.25.

What is the AlleAktien quality score of Agios Pharmaceuticals?

The AlleAktien quality score for Agios Pharmaceuticals is 5/10.

What is the revenue of Agios Pharmaceuticals 2024?

The expected Agios Pharmaceuticals revenue is 38.84 M USD.

How high is the profit of Agios Pharmaceuticals 2024?

The expected Agios Pharmaceuticals profit is -286.66 M USD.

What is the business model of Agios Pharmaceuticals

Agios Pharmaceuticals Inc. is an emerging biotechnology company specializing in the development of drugs for the treatment of cancer and rare genetic diseases. The company was founded in 2008 by a team of renowned scientists and has since built an impressive product pipeline. Agios has two main business divisions: cancer and rare metabolic disorders. In cancer research, Agios focuses on the discovery of metabolic processes that contribute to the formation of tumors. The company has several drugs in clinical development that target these processes, including Idhifa for the treatment of acute myeloid leukemia and TIBSOVO for the treatment of certain types of advanced cancer. In the rare metabolic disorders division, Agios is a leader in the research of Duchenne muscular dystrophy (DMD) and thalassemia. DMD is a progressive genetic disease that weakens the muscles and often leads to death. Agios is researching a therapy that improves the disrupted metabolic pathway in DMD patients. In addition to TIBSOVO, the company is also developing ivosidenib, a drug for the treatment of high-grade gliomas and cholangiocarcinoma. Agios' business model is based on four pillars. Firstly, the company is committed to conducting science and research. It invests 25-30% of its revenue annually in research and development to bring new drugs to market that can improve patients' lives. Secondly, the company has a partnership with Celgene Corp. for TIBSOVO and ivosidenib. Celgene assists in financing the development and takes care of the sales and marketing of the products. Thirdly, Agios has a joint research agreement with Celgene for the exploration of new cancer drugs. Finally, Agios' pipeline will also be commercialized and distributed once approved by the FDA and other regulatory agencies. Overall, Agios Pharmaceuticals is an emerging biotechnology company with an impressive portfolio of cancer and rare metabolic disorder drugs. The company heavily invests in research and development of new drugs and works closely with partners and regulatory authorities to bring these drugs to market and make them accessible.

What is the Agios Pharmaceuticals dividend?

Agios Pharmaceuticals pays a dividend of 0 USD distributed over payouts per year.

How often does Agios Pharmaceuticals pay dividends?

The dividend cannot currently be calculated for Agios Pharmaceuticals or the company does not pay out a dividend.

What is the Agios Pharmaceuticals ISIN?

The ISIN of Agios Pharmaceuticals is US00847X1046.

What is the Agios Pharmaceuticals WKN?

The WKN of Agios Pharmaceuticals is A1W2RM.

What is the Agios Pharmaceuticals ticker?

The ticker of Agios Pharmaceuticals is AGIO.

How much dividend does Agios Pharmaceuticals pay?

Over the past 12 months, Agios Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Agios Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Agios Pharmaceuticals?

The current dividend yield of Agios Pharmaceuticals is .

When does Agios Pharmaceuticals pay dividends?

Agios Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Agios Pharmaceuticals?

Agios Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Agios Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Agios Pharmaceuticals located?

Agios Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Agios Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Agios Pharmaceuticals from 9/26/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/26/2024.

When did Agios Pharmaceuticals pay the last dividend?

The last dividend was paid out on 9/26/2024.

What was the dividend of Agios Pharmaceuticals in the year 2023?

In the year 2023, Agios Pharmaceuticals distributed 0 USD as dividends.

In which currency does Agios Pharmaceuticals pay out the dividend?

The dividends of Agios Pharmaceuticals are distributed in USD.

All fundamentals about Agios Pharmaceuticals

Our stock analysis for Agios Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Agios Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.